Ask a woman 6 months into a GLP-1 how it's going and she will usually tell you the number first. Down 32 pounds. Down 45. The number is doing exactly what she was promised it would do.

Then ask her a second question, and the answer changes shape.

She is tired in a way that sleep is not fixing. There is more hair in the drain than there used to be. And the face in the mirror looks older than the number on the scale says it should, in a way she finds hard to explain to anyone who hasn't seen it happen to them.

Most women assume this is the drug. It is more specific than that, and the people who see it every day are not the prescribers. They're the dietitians.

There is one number in the research that explains most of it. Once you know it, you can work out in about 10 seconds whether it applies to you. We'll get to it.

In 2024, researchers sat down with 13 registered dietitians who counsel patients on GLP-1 medications and asked them what the job actually involves. The interviews ran 30 to 45 minutes each and were published as a qualitative study.

The dietitians kept returning to the same problem, and it wasn't appetite.

Protein is the part that made it out of the clinic and onto the shelf. Every GLP-1 product you have been served an ad for is protein, or a version of protein.

The first two quotes are the part that didn't.

A 2025 study in Frontiers in Nutrition did something simple and, it turns out, revealing. Researchers took 3-day food records from 69 people on GLP-1 medication, 55 of them women, average age 49. Then they added up what was actually going in.

Average intake came to 1,748 calories a day. For the women in the study it was 1,700. That is roughly 30% less food than the typical intake these women were eating before.

Fewer calories was the point. The problem is that calories are not the only thing that came down.

Measured against recommended intakes, the group fell short on fiber, calcium, iron, magnesium, potassium, choline, and vitamins A, C, D, E and K.

That is 11 shortfalls in a group of people who, by every visible measure, were succeeding.

Choline is the one on that list of 11 that your brain uses to build acetylcholine, the chemical behind memory and focus. It is also a building block of the membrane around every cell you own.

It is not on any GLP-1 support label we could find. It is not in a protein shake. It is in eggs, liver and fish, in quantities that require eating a normal amount of food.

Here is the 10-second version we promised. If you are on a GLP-1 and you can list everything you ate yesterday from memory, without effort, because there was so little of it, you are almost certainly in the 94.2%.

That is not a moral failure and it is not a reason to stop the medication. It is arithmetic. You cannot eat 30% less food and take in the same amount of everything that was in it.

The timing is not random, and hair is the clearest example of why.

A 2026 systematic review in Science Progress looked at hair loss during GLP-1 therapy. Shedding does not begin when the shortfall begins. It runs on the hair follicle's own clock and appears roughly 2 to 3 months later. Regrowth does not start until weight stabilizes, and visible density takes months more after that.

The same review found women affected at more than double the rate of men. In one analysis the adjusted hazard ratio for women on semaglutide was 2.08, against 0.86 for men.

So the shortfall starts in month 2 or 3, and the mirror reports it in month 5 or 6. By the time a woman notices, she has been running on a deficit for a season.

Energy follows a similar lag, for a similar reason. The body spends its reserves quietly before it tells you.

In May 2025, four organizations, the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association and The Obesity Society, published a joint advisory on nutrition during GLP-1 therapy. It set protein targets of 1.2 to 1.6 g/kg and flagged both inadequate nutrient intake and loss of muscle and bone as real risks of the treatment.

The industry heard the protein half. Here is what the GLP-1 shelf currently offers.

Read across the table and the pattern is hard to miss. The market has built the protein column 5 times over and left the other two empty.

Everbright is a daily capsule made by Melina, a women's brain health company. It was formulated for women in perimenopause and menopause, whose cells are under a comparable kind of strain for an unrelated reason. Nobody at the company was thinking about GLP-1 medication when it was designed.

Which is why it is an odd fit on paper and a close one in practice. 2 capsules contain:

Citicoline, 200 mg. A delivered form of choline that the brain uses to build acetylcholine and to repair cell membranes. In a 12-week trial in older adults, citicoline supplementation improved memory performance, particularly episodic memory.

Nicotinamide riboside, 300 mg. A precursor to NAD+, the molecule your cells use to turn food into usable energy and to repair DNA.

Astaxanthin, grape seed extract and pterostilbene. Three antioxidants with human data on skin elasticity, circulation and oxidative stress. This is the column the GLP-1 shelf does not stock at all.

There is no clinical trial of Everbright in women taking GLP-1 medication. We are not going to pretend otherwise. What there is: a documented shortfall list, a formula whose 5 ingredients sit on top of 3 of the items on that list, and 30 days to find out whether it does anything for you.

The medication is doing its job. The food math underneath it is doing something nobody warned you about, and month 6 is roughly when you see it in the mirror rather than in a number.

Get the protein. Get the labs. And if the tired, the hair and the face all arrived at once, the missing column is worth 30 days of your attention.